rebalancing novo nordisk: the company has a hold on the diabetes market, but can it diversify into new areas of medicine? a snapshot of the company and its need for m&amp;a after its attempt to acquire ablynx failed. via @ap $ $ablx #biotech #pharma https://t.co/yxcqshmtcj